Newbury Pharmaceuticals
1.33 SEK
-1.12 %
Less than 1K followers
NEWBRY
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Newbury Pharmaceuticals
| 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | Q1/26 | Q2/26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 36.8 | 6.5 | 12.4 | 6.7 | 5.9 | 31.6 | 11.7 | 8.5 |
| EBITDA | -12.3 | -3.8 | -1.0 | -5.7 | -5.9 | -16.3 | -5.5 | -3.7 |
| EBIT | -14.1 | -4.2 | -1.4 | -6.2 | -10.1 | -22.0 | -6.1 | -4.1 |
| EBIT-% | -38.2 % | -64.7 % | -11.6 % | -92.2 % | -171.1 % | -69.6 % | -52.2 % | -49.0 % |
| Profit before taxes | -15.4 | -4.6 | -1.9 | -6.6 | -10.5 | -23.6 | -6.5 | -4.6 |
| Net income | -15.4 | -4.6 | -1.9 | -6.6 | -10.8 | -23.9 | -6.5 | -4.6 |